AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Phase 1 Recruiting 48 enrolled Amylyx Pharmaceuticals Inc.

RandomizedSequentialQuadruple-blindTreatment

Summary

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

Timeline

Start: 2025-04-07
Primary completion: 2027-02
Completion: 2027-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AMX0114	Unknown	—	Intrathecal

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Summary

Timeline

Drugs

Indications